Objective To investigate the effect of ipratropium bromide combined with flixotide on children with acute asthma exacerbation.Methods A total of 128 children with acute asthma exacerbation admitted to our hospital from January 2021 to June 2023 were enrolled in this trial,and they were divided into two groups using random number table methods.The patients in the control group(n=65)were treated with flixotide inhalation,and thsoe in the observation group(n=63)with ipratropium bromide inhalation on the basis of treatment regime in the control.The TCM symptom score,immune function,clinical efficacy and occurrence of adverse reactions were compared between the 2 groups.Results After treatment,the daytime and evening symptom scores of the two groups were lower than those before treatment(P<0.05).They were(0.21±0.04)and(0.62±0.16)scores in the observation group,which were significantly lower than(0.30±0.08),and(0.69±0.15)scores in the control group(P<0.05).Compared with those before treatment,the levels of IgM,IgG and IgA in the two groups increased after treatment(P<0.05),and the three indexes were(5.92±1.41)g·L-1,(10.42±1.73)g·L-1 and(7.28±0.84)g·L-1 in the observation group,which were larger than those of(4.81±0.65)g·L-1,(8.98±1.44)g·L-1 and(6.38±0.81)g·L-1 in the control(P<0.05).The observation group reported a higher clinical efficacy rate than the control[96.83%(61/63)vs.84.62%(55/65),P<0.05].There was no statistical difference in adverse reaction rate between the two groups(P>0.05).Conclusion Application of ipratropium bromide combined with flixotide for children with acute asthma exacerbation can effectively improve immune function and prognosis and there is no major increase in incidence.
AsthmaAcute exacerbationIpratropium bromideFlixotideImmune function
NETL
NSTL
万方数据
